Paratek Pharmaceuticals (PRTK)

Executive Summary

Paratek Pharmaceuticals is a Boston-based biopharmaceutical company focused on developing and commercializing innovative therapies for life-threatening infectious diseases and difficult-to-treat conditions. The company's marketed portfolio includes NUZYRA (omadacycline), a broad-spectrum antibiotic for community-acquired pneumonia and skin infections, and XHANCE (fluticasone propionate), a nasal spray for chronic rhinosinusitis with nasal polyps. Paratek is dedicated to combating antimicrobial resistance and addressing significant unmet medical needs in specialty care. Since its acquisition by Gurnet Point in 2023, the company operates as a private entity, allowing it to focus on long-term growth and product lifecycle expansion without quarterly earnings pressure. Paratek's commercial strategy emphasizes expanding NUZYRA's hospital penetration and growing XHANCE's market share through targeted physician education and patient access programs. The company continues to invest in clinical development to broaden label indications and strengthen its pipeline. Key upcoming catalysts include potential label expansions for both products and strategic partnerships to maximize global reach. With approved products generating steady revenue and a clear focus on high-need areas, Paratek is well-positioned for sustainable growth.

Upcoming Catalysts (preview)

• Q1 2027FDA approval of XHANCE for acute rhinosinusitis (new indication)55% success
• Q4 2026Positive Phase 3 data for NUZYRA in hospital-acquired pneumonia40% success
• H2 2026Licensing agreement for NUZYRA ex-U.S. rights60% success